| Co-Investigator(Kenkyū-buntansha) |
森 稔幸 順天堂大学, 医学部, 助教 (00462739)
池田 美恵 順天堂大学, 大学院医学研究科, 学振特別研究員(RPD) (40734314)
バリカガラ ベテイ 順天堂大学, 大学院医学研究科, 助教 (70805895)
堀井 俊宏 大阪大学, 微生物病研究所, 寄附研究部門教授 (80142305)
|
|---|
| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2021: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
Malaria is one of the world's three major infectious diseases, causing 200 million infections and 600,000 deaths each year. Although the first-line drug artemisinin has greatly reduced the number of deaths, resistant parasites have already emerged and spread from the Greater Mekong sub-region. There are concerns about their spread. This study aims to clarify the emergence and spread of global artemisinin resistance through international collaboration. As a result of this study, we found that in vivo resistance emerged in 2021, that the causative mutations were A675V and C469Y in K13, and that both resistance mutations originated in Africa, not Southeast Asia. This was published in the New England Journal of Medicine in 2021.
|
